Photo of Kristin Bahner
D Minnesota House · District 37B On the 2026 ballot

Rep. Kristin Bahner

Compare
Total votes
2,491
all sessions
Attendance
99%
16 missed
Near the chamber average
With party
99%
of cast votes
Near the chamber average
Bipartisan score
0%
crosses aisle rarely
Near the chamber average
Sponsored
833
bills & resolutions
Near the chamber average
Committees
3
assignments
833 bills and resolutions

Sponsored bills

Total
833
Primary
152
Co-sponsor
681
This page
833
matching current filters
Co-sponsor HF 5470
In committee · Minnesota House · Co-sponsor
Pharmacy benefit manager business practices modified, pharmacy benefit manager general reimbursement practices established, and maximum allowable cost pricing requirements modified.

Maddy summaryThis bill regulates how pharmacy benefit managers operate in Minnesota by establishing clearer rules for reimbursement and pricing. It directly affects pharmacy benefit managers, pharmacies, and health insurance plans by requiring fair dealing and prohibiting deceptive practices. Key provisions ban charging pharmacies fees for processing claims, forbid paying pharmacies less than the rates given to the manager's own affiliates, and explicitly outlaw the use of spread pricing. Additionally, the law mandates that managers provide transparent pricing data to pharmacies and update these lists frequently when drug costs rise significantly.

In committee May 13, 2024 1 co-sponsor
Co-sponsor HF 5469
In committee · Minnesota House · Co-sponsor
Pharmacy benefit managers and health carriers required to include lower-cost drugs in their formularies, and formulary structure and formulary tiering for each health plan required to give preference to drug with lowest out-of-pocket cost to patient.

Maddy summaryThis bill requires pharmacy benefit managers and health carriers in Minnesota to include lower-cost generic and biosimilar drugs on their drug lists whenever a more expensive brand-name version is covered. It mandates that these plans structure their coverage tiers to prioritize medications that result in the lowest out-of-pocket costs for patients, such as co-pays and coinsurance. Additionally, the law forces plans to immediately add new generic or biosimilar drugs to their lists if they are cheaper than existing options and removes barriers like prior authorization for the lowest-cost alternatives. These changes directly affect health insurance companies and pharmacy benefit managers by altering how they select and organize covered medications to reduce expenses for individuals.

In committee May 13, 2024 1 co-sponsor
Showing 181 to 190 of 833 bills
Previous 1 … 18 19 20 … 84 Next